PIPELINE WATCH: A Strong Analgesic Meets Primary Endpoint, But An RNAi Therapeutic Disappoints
Executive Summary
Pipeline Watch has been updated to bring greater depth and detail to a product’s progress through the R&D pipeline, and is now a snapshot of late-stage, Phase II and III clinical trial events for drugs being evaluated by the pharma and biotech industries that is now available to view.